Cellular Immunity and Levels of Parathyroid Hormone in Uremic Patients Receiving Hemodialysis
| Autor: | Efstathios Mitsopoulos, Alexandra Fleva, E. Ginikopoulou, D. Meimaridou, E. Manou, P. Kyriklidou, G. Sakellariou, A. Paulitou, R. Zilidou, Dorothea Papadopoulou, Georgios Visvardis, Ioannis Griveas |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Nephrology
medicine.medical_specialty Cellular immunity business.industry Lymphocyte medicine.medical_treatment Parathyroid hormone General Medicine Critical Care and Intensive Care Medicine medicine.disease medicine.anatomical_structure Endocrinology Internal medicine medicine Population study Analysis of variance Hemodialysis business Kidney disease |
| Zdroj: | Renal Failure. 27:275-278 |
| ISSN: | 1525-6049 0886-022X |
| Popis: | Objective: The clinical relevance of altered lymphocyte function and the possible relation with uremic toxins, such as parathyroid hormone (PTH) is not well understood. We studied the changes in cellular immunity in patients in hemodialysis (HD) therapy and examined the relationship between T-lymphocyte function and plasma levels of PTH. Patients and Methods: Thirty-four patients (14 male) were enrolled in this study (mean age: 63.20 ± 10.01 years, M ± SD, 12 h/week HD). Our study population was divided into two groups: 18 patients with increased levels of PTH and 16 patients with normal levels of PTH. Lymphocyte subsets (CD2 +, CD3 +, CD3 +/4 +, CD3 +/8 +, CD19 +, CD3-/16 + 56 +, CD4/CD8 ratio) were quantitated in both groups using monoclonal antibodies (Immunotech, Coulter) and flow cytometric analysis. Following analysis of variance (ANOVA) testing was performed to test differences between groups (SPSS version 10). Results: A significant increase of CD2 was noticed in patients with increased levels of ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |